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Late onset systemic lupus erythematosus in
southern Chinese
Carmen Tze Kwan Ho, Chi Chiu Mok, Chak Sing Lau, Raymond Woon Sing Wong
Abstract
Objective—Systemic lupus erythematosus
(SLE) is a multisystem disorder that pre-
dominately aVects women of the repro-
ductive age. Onset of the disease beyond
the age of 50 years is unusual. This study
was undertaken to compare retrospec-
tively the clinical and laboratory features
between early and late onset (onset of dis-
ease beyond the age of 50 years) SLE
patients in a Chinese population.
Methods—Case records of all SLE pa-
tients who attended our rheumatology
clinics between 1971 and 1997 were re-
viewed. Patients with a disease onset
beyond the age of 50 years were identified.
One hundred consecutive SLE patients
who had their disease onset before the age
of 50 were recruited as controls. The
presenting clinical features, autoantibody
profile, number of major organs involved,
number of major relapses, and the use of
cytotoxic agents in the two groups of
patients were obtained and compared.
Results—25 patients with late onset SLE
were identified. All the female patients in
the late onset group were postmenopau-
sal. The female to male ratio was 3.2 to 1,
compared with 13.3 to 1 in the control
group (p<0.02). Both groups had a com-
parable duration of disease. There were no
significant diVerences in the presenting
features between the two groups except for
a lower prevalence of malar rash (24% v
86%, p<0.0001) and a higher prevalence of
rheumatoid factor (32% v 1%, p<0.0001) in
the late onset patients. On subsequent
visits, the late onset group had a lower
prevalence of lupus nephritis (4% v 51%,
p<0.001), fewer major organs involved
(mean number of major organs involved;
0.3 v 0.9, p<0.02), fewer major relapses
(mean number of major relapses/patient;
0.08 v 0.47, p<0.002, number of major
relapses/patient year; 0.009 v 0.12,
p<0.001), and required fewer cytotoxic
agents for disease control (percentage of
patients on cytotoxic agents; 32% v 79%,
p<0.002).
Conclusion—Late onset SLE in Chinese
tends to run a more benign course with
fewer major organ involvement and fewer
major relapses. The significantly higher
incidence of male sex in late onset SLE
and the milder disease course in the post-
menopausal female patients suggest that
oestrogen status may influence disease
activity.
(Ann Rheum Dis 1998;57:437–440)
Systemic lupus erythematosus (SLE) pre-
dominantly aVects women of reproductive
age. It is characterised by a broad range of
clinical and laboratory manifestations and is
notable for a variable course, prognosis, and
response to treatment. Because of such
heterogeneity, attempts have been made to
identify subsets of patients that would permit
more accurate prediction of the course of
illness in aVected people. Onset of SLE
beyond the age of 50 years is unusual. This
group of patients has been reported to have a
clinical presentation diVerent from that seen in
younger patients. This study was undertaken
to compare retrospectively the clinical, labora-
tory, and immunological features between
early and late onset SLE patients in a Chinese
population.
Methods
PATIENTS
All case records of an inception cohort of SLE
patients who attended our rheumatology
clinics between 1971–1997 were reviewed. All
patients were ethnic Chinese and fulfilled at
least four of the American Rheumatology
Association criteria for the classification of
SLE.1 Patients with disease onset beyond the
age of 50 years were identified—the late onset
SLE group. One hundred consecutive case
records of patients whose first disease
manifestations occurred before the age
of 50 years were selected as controls. All
patients were followed up at least three
monthly, or more frequently if necessary, for
example, during a disease flare. The
presenting clinical features, autoantibody
profile, number of major organs involved,
number of major relapses, and the use of
immunosuppressive agents in both groups of
patients were recorded. Major organ involve-
ment was defined as involvement of an organ/
system to the extent that high dose
prednisolone (>0.5 mg/kg/day) with or
without cytotoxic agents were needed for
disease control. These included nephritis
(WHO class III–V), severe serositis, neuropsy-
chiatric lupus, transverse myelitis, pulmonary
haemorrhage, severe thrombocytopenia (<20
× 109/l), and haemolytic anaemia. Joint and
skin diseases were not included. A major
relapse was defined as a severe disease flare
that was accompanied by the need to start or
augment the dose of prednisolone to more
than 0.5mg/kg/day with or without the subse-
quent use of cytotoxic agents, based on clinical
grounds.
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STATISTICAL ANALYSIS
Comparison of non-parametric data between
the two groups of patients was made by using
the ÷2 test. Fisher’s exact test was used
whenever the number was small. For compari-
son of parametric data, the Student t test was
adopted. Because of multiple comparisons,
only diVerences at p<0.01 were considered
statistically significant.
Results
Three hundred case records were reviewed.
Ten were excluded because of missing or
incomplete case notes. From the remaining
pool of patients, 100 consecutive SLE patients
who had a disease onset before the age of 50
were selected as controls for comparison. The
mean (SD) age of onset of SLE for the control
and late onset groups were 28.3 (8.5) years
(range: 13–47) and 63.3 (10.6) years (range:
51–86), respectively (p<0.0001). The female/
male ratio of the control patients was 13.3:1
(93 females and 7 males) and that of the late
onset group was 3.2:1 (19 females and 6 males,
p<0.02). All our female late onset SLE patients
were postmenopausal and none of them were
receiving hormonal replacement therapy. The
mean time interval between the onset of symp-
toms to the diagnosis of SLE was shorter in the
controls (1.7 (3.2) months) than the late onset
patients (5 (14.2) months) but the diVerence
did not reach statistical significance. The dura-
tion of disease was comparable in the two
groups of patients (5.6 (4.4) years for the con-
trols and 5.7 (5.5) years for the late onset SLE
patients, p=1.00).
Table 1 lists the frequency of SLE clinical
manifestations and laboratory findings at pres-
entation and during subsequent follow up for
the two groups of patients. There were no sig-
nificant diVerences in clinical features at
presentation between the two groups except
that control patients had a significantly higher
incidence of malar rash (86% v 24%,
p<0.0001) and lower incidence of rheumatoid
factor (1% v 32%, p<0.0001). During follow
up, late onset SLE patients had a significantly
lower incidence of biopsy confirmed lupus
nephritis (4% v 51%, p<0.001).
Late onset lupus patients had significantly
less major organ involvement when compared
with controls (mean number of major organs
involved/patient in the late onset group and
controls were 0.3 and 0.9, respectively;
p<0.02). The mean number of major relapses
per patient (0.08 in late onset group v 0.47 in
controls; p<0.002) and number of major
relapses per patient year of follow up (0.009 v
0.12; p<0.001) were also significantly lower in
this group. Use of cytotoxic agents for disease
control was less likely in the late onset than the
control group (32% v 79%, p<0.002). Seven
(28%) patients in the late onset group and 61
(61%) patients in the control group were given
azathioprine, and one (4%) patient in the late
onset group and 18 (18%) patients in the con-
trol group were given cyclophosphamide for
the treatment of class IV nephritis.
Two late onset SLE patients died during the
study period. One died at the age of 69 of sub-
arachnoid haemorrhage, which was unrelated
to her lupus disease. The other, aged 76, died
of septicaemia complicating a perforated
bowel. Whether the second death was related
to the lupus process was not clear because the
patient’s relatives declined a postmortem
examination. None died in the control group
during the study period.
Table 1 Frequency of clinical manifestations and laboratory findings at presentation and during follow up in late onset
(n=25) and control (n=100) lupus patients
Clinical features
Initial presentation During follow up
late onset
n (%)
control
n (%) p value
late onset
n (%)
control
n (%) p value
Malar rash 6 (24) 86 (86) <0.0001 7 (28) 86 (86) <0.0001
Discoid rash 0 (0) 8 (8) 0.1 0 (0) 8 (8) 0.31
Photosensitivity 2 (8) 26 (26) 0.10 2 (8) 27 (27) 0.08
Serositis 2 (8) 8 (8) 0.68 3 (12) 8 (8) 0.81
Oral ulcer 5 (20) 8 (8) 0.16 5 (20) 9 (9) 0.23
Arthritis 19 (76) 86 (86) 0.36 21 (84) 86 (86) 0.95
Alopecia 4 (16) 26 (26) 0.43 4 (16) 26 (26) 0.43
Keratoconjunctivitis sicca 2 (8) 1 (1) 0.19 3 (12) 1 (1) 0.03
Raynaud’s phenomenon 1 (4) 8 (8) 0.80 2 (8) 8 (8) 0.68
Fever 10 (40) 18 (18) 0.02 10 (40) 18 (18) 0.02
Myalgia 0 (0) 7 (7) 0.38 1 (4) 7 (7) 0.93
CNS involvement* 0 (0) 4 (4) 0.70 0 (0) 4 (4) 0.70
Nephritis† 0 (0) 9 (9) 0.26 1 (4) 51 (51) <0.001
Pancytopenia‡ 1 (4) 5 (5) 0.75 1 (4) 5 (5) 0.75
Lymphopenia‡ 9 (36) 38 (38) 0.85 11 (44) 38 (38) 0.58
Haemolytic anaemia 3 (12) 20 (20) 0.53 5 (20) 20 (20) 0.78
Thrombocytopenia‡ 4 (16) 25 (25) 0.49 5 (20) 25 (25) 0.79
Anti-nuclear antibody 25 (100) 99 (99) 0.45 25 (100) 99 (99) 0.45
Anti-dsDNA antibody 18 (72) 79 (79) 0.45 21 (84) 79 (79) 0.78
Anti-Ro antibody 15 (60) 51 (51) 0.42 15 (60) 53 (53) 0.53
Anti-La antibody 2 (8) 8 (8) 0.68 2 (8) 9 (9) 0.81
Anti-Sm antibody 5 (20) 9 (9) 0.23 6 (24) 9 (9) 0.09
Anti-RNP antibody 5 (20) 17 (17) 0.95 5 (20) 19 (19) 0.86
Rheumatoid factor 8 (32) 1 (1) <0.001 8 (32) 1 (1) <0.0001
*CNS = central nervous system, referring to neuropsychiatric involvement based on the 1982 ACR revised criteria of SLE1 (that is,
psychosis and seizure). †Nephritis = biopsy confirmed lupus nephritis. ‡Pancytopenia = total leucocyte count <3.5×109/l plus haemo-
globin <11 g/dl plus platelet count <130×109/l on at least two occasions. Lymphopenia = peripheral lymphocyte count <1.5×109/l
on at least two occasions. Thrombocytopenia = platelet count <130×109/l on at least two occasions. Anti-nuclear antibodies were
detected by indirect immunofluorescence. Anti-dsDNA antibody was detected by the Crithidia assay before 1992, and ELISA since
then.Anti-ENA antibodies were detected using the counter-current immunoelectrophoresis. Rheumatoid factor was assayed by latex
agglutination before 1991, and ELISA since then.
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Discussion
Many previous studies2–9 have suggested that
late onset SLE patients diVer from those
with early onset in clinical presentation,
pattern of organ involvement, severity of
disease, and prognosis. Additionally, there may
be inter-ethnic diVerences in some of these
clinical features. SLE is relatively common
among Chinese in Hong Kong.10 However,
there has so far been only one publication11 on
late onset lupus in Chinese patients. Our main
objective was therefore to determine whether
the above concept holds for our Chinese
population.
Our study is in accordance with most
previously reported series of a less pronounced
female predominance in SLE patients whose
disease first presented later in life.2–9 11 12 This
leads to the postulation that female sex
hormones may play a part in determining the
expression of the disease. Lupus may appear,
or the disease may exacerbate, when serum
concentrations of reproductive hormones
change rapidly. In the pre-corticosteroid era,
improvement was noted after the patient had
reached menopause or had surgical removal of
the uterus and ovaries.13 This suggests that
oestrogen status may be important in deter-
mining disease activity in SLE.
In our study, the interval between symptom
onset and the diagnosis of SLE was found to
be longer in the late onset group than the con-
trols, although the diVerence did not reach
statistical significance. Similar results have
been suggested previously.2 4 5 7 9 This illus-
trates that late onset SLE patients may present
atypically at disease onset, leading to a delay in
diagnosis. In fact, six of our patients fulfilled
only three ARA criteria for SLE at presenta-
tion, when the diagnosis was uncertain. Four
of them developed more features of SLE on
follow up while two remained labelled as hav-
ing lupus-like disease because no new features
evolved. These two patients had positive ANA,
positive anti-dsDNA, anti-Ro and thrombocy-
topenia and had been excluded from our
analysis.
The clinical presentation of late onset SLE
patients varies in diVerent series. Commonly
reported clinical features include fever, weight
loss, musculoskeletal complaints, arthritis,
oral ulcers, and pleuropericarditis. Wilson et
al3 and Maddison5 also described an increased
prevalence of Raynaud’s phenomenon, inter-
stitial lung disease, and cutaneous and neu-
ropsychiatric involvement in elderly lupus
patients. Late onset lupus patients in the
present study had a significantly lower inci-
dence of malar rash and lupus nephritis when
compared with younger lupus patients. Ray-
naud’s phenomenon was less common al-
though this might be related to the warmer
climate in Hong Kong. In late onset lupus
patients, there appeared to be a higher preva-
lence of sicca complex (12% v 1%) though the
diVerence was not statistically significant.
Only Maddison5 and Catoggio et al7 had
reported the frequency of sicca complex (42%
and 38%, respectively) in their studies. As our
study was conducted retrospectively, underes-
timation could not be avoided and confirma-
tory tests (for example, Schirmer’s test and
salivary gland biopsy) were not performed in
some of the patients. Therefore, the true
prevalence of Sjogren’s syndrome could have
been higher.
Table 2 shows a comparison of the autoanti-
body profile of late onset lupus patients from
five diVerent studies including this one. As can
be noted, anti-Ro and anti-La antibodies were
more commonly found in white patients5–7
while Chinese patients showed a higher fre-
quency for anti-Sm and anti-nRNP antibodies.
It should, however, be noted that some of these
diVerences may have partially been related to
diVerent procedures used to assay the various
antibodies. Among our patients, the autoanti-
body profile of those with late disease onset did
not diVer significantly from that of control
patients. Only RF was more commonly found
in the late onset group. This could be explained
by the fact that RF is more commonly found in
the older population. Despite the high preva-
lence of anti-dsDNA (which was comparable
to the control group) in our late onset SLE
patients, they had fewer major organs involved
when compared with the younger lupus
patients. In addition, late onset SLE patients
had a milder disease course, which was
reflected by the significantly lower mean
number of major relapses per patient, number
of major relapses per patient year, and that
fewer patients required the use of cytotoxic
agents for disease control during the course of
their disease.
In conclusion, our retrospective study of
Chinese SLE patients showed diVerences in
disease onset, pattern of organ involvement,
and serology between the late and early onset
groups. Late onset SLE patients have a milder
disease course with fewer major organs in-
volved, fewer major relapses, and less aggres-
sive immunosuppression required for disease
control. Prospective studies involving a larger
number of late onset SLE patients are needed
to confirm whether they constitute a distinct
subset of SLE regarding clinical presentation
and prognosis.
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